The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Objective To update the evidence on efficacy and safety of biological disease-modifying
antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the …

Biotechnological monoclonal antibodies and receptor antagonists capable of targeting
specific inflammatory actors, such as cytokines, cytokines receptors, co-stimulatory …

Over the last 30 years the role of monoclonal antibodies in therapeutics has increased
enormously, revolutionizing treatment in most medical specialties, including neurology …

The treatment of patients with axial spondyloarthritis (axSpA) is characterized by non-
pharmacological and pharmacological treatment options. It may depend on the type and …

The past decades have yielded major therapeutic advances in many autoimmune conditions–
such as multiple sclerosis (MS)–and thus ushered in a new era of more targeted and …

Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to inform the 2022 …

Multiple sclerosis (MS) is the most common disabling disease of the central nervous system
(CNS) with a progressive neurodegenerative pattern. It is characterized by demyelination of …

Background and Objectives Antitumor necrosis factor α (TNFα) agents are a class of biologic
drugs used for the treatment of several immune-mediated conditions. An increased risk of …

Objective To establish the incidence of demyelination in patients who have received anti–
tumor necrosis factor alpha (anti-TNFα) therapy, through analysis of adverse events reported …